Claims
- 1. A method of treating bacterial pneumonia in a mammal comprising administering to the mammal a therapeutically effective amount of an anti-IL-8 monoclonal antibody having the following characteristics: ability to bind human IL-8 with a Kd between about 1.times.10.sup.-8 to about 1.times.10.sup.-11 M, ability to inhibit neutrophil chemotaxis in response to IL-8, and ability to inhibit IL-8 mediated elastase release by neutrophils; wherein the monoclonal antibody does not bind to C5a, .beta.-TG or platelet factor 4.
- 2. The method of claim 1 wherein the mammal is a human.
- 3. The method of claim 1 wherein the bacterial pneumonia is caused by Streptococcus pneumoniae, Escherichia coli, or Pseudomonas aeruginosa.
- 4. The method of claim 1, wherein the antibody comprises an antigen binding site comprising the complementarity determining regions of the light chain polypeptide of FIG. 24 (SEQ ID NO:48) and the complementarity determining regions of the heavy chain polypeptide of FIG. 25 (SEQ ID NO:50).
- 5. The method of claim 1, wherein the antibody comprises an antigen binding site comprising the complementarity determining regions of the light chain polypeptide of FIG. 16 (SEQ ID NO:20) and the complementarity determining regions of the heavy chain polypeptide of FIG. 17 (SEQ ID NO:22).
Parent Case Info
This application is a continuation-in-part of U.S. Ser. No. 08/205,864, filed Mar. 3, 1994, now abandoned, which is specifically incorporated by reference herein in its entirety.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4816567 |
Cabilly et al. |
Mar 1989 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
454225 A1 |
Oct 1991 |
EPX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
205864 |
Mar 1994 |
|